Cancer Stem Cell Development is Documented
Posted on: Monday, 22 January 2007, 18:00 CST
U.S. scientists have clarified how normal stem cells become cancer stem cells, as well as how cancer stem cells can cause the formation of tumors.
Dr. Xi He and associate investigator Linheng Li, both with the Stowers Institute for Medical Research, studied the intestinal system in mice in which one of the human tumor suppressor genes, PTEN, had been deleted.
We found that a loss of PTEN in intestinal epithelial cells accompanied by a loss of PTEN in stromal cells can lead to changes that may increase the number of stem cells and change their position or location, said Li. These changes result in crypt fission and budding and can lead to intestinal polyposis and uncontrolled tumor growth.
What we learned, added He, is that cancer stem cells are a rare population in the tumor mass; that they are slow cycling, but more active than normal stem cells; and that cancer stem cells and stromal insertions initiate the process of primary tumorigenesis ...
The study appears on the Nature Genetics journal's Web site.
Source: United Press International
Related Articles
- Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test to Select Patient Candidates for Novel Investigational Non-Small Cell Lung Cancer Therapy
- Research Provides Documentation That Tumor 'Stem-Like Cells' Exist In Benign Tumors
- Discovery Pinpoints New Link Between Cancer Cells, Stem Cells
- Data From Studies of Amrubicin in Small-Cell Lung Cancer Presented at the 2008 American Society of Clinical Oncology Meeting Demonstrate Single Agent Anti-Tumor Activity in Western Patient Population
- Sunesis Pharmaceuticals Reports Positive Initial Results From Phase 2 Small Cell Lung Cancer Trial With SNS-595
- Study Reinforces Potential Utility of ONCONASE(R) in Non-Small-Cell Lung Cancer
- OSI Pharmaceuticals Launches Study of Tarceva(R) As Adjuvant Treatment for Non-Small Cell Lung Cancer
- Comparison of Different Methods for Delineation of ^Sup 18^F-FDG PET- Positive Tissue for Target Volume Definition in Radiotherapy of Patients With Non-Small Cell Lung Cancer
- Biological Variation of Tumor Markers and Its Application in the Detection of Disease Progression in Patients With Non-Small Cell Lung Cancer
- Point Therapeutics Achieves Interim Tumor Response Criteria in Phase 2 Non-Small Cell Lung Cancer Study; Company Advances Talabostat to Second Stage of Study
 |
 |
User Comments (0)
RSS Feeds